SY1:XETRSymrise AG Analysis
Data as of 2026-05-18 - not real-time
€75.48
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Symrise is trading just above its short‑term moving average while the longer‑term average lags slightly, leaving the price in a neutral technical zone. The RSI sits in the mid‑range, indicating no clear overbought or oversold condition. A bearish MACD histogram points to modest downward momentum, yet the overall trend remains flat. Beta is essentially flat, suggesting the stock moves independently of broader market swings. Volatility over the past month is moderate, implying price swings that could be exploitable for short‑term traders. The current price is well above the DCF‑derived fair value, flagging a significant valuation gap.
Fundamentally, revenue has slipped slightly year‑over‑year while margins stay in the mid‑range, and the forward earnings estimate implies a much lower PE than the trailing figure, hinting at potential earnings improvement. The dividend yield is modest, backed by positive free cash flow and a payout ratio comfortably below the majority of earnings, suggesting sustainability. Analyst consensus remains bullish with a “buy” rating and price targets in the upper range of expectations, reflecting optimism despite the valuation stretch. The Fear & Greed index is in the extreme greed zone, which may signal market euphoria. Given these mixed signals, investors should weigh the overvaluation against the steady cash generation and dividend stability.
Fundamentally, revenue has slipped slightly year‑over‑year while margins stay in the mid‑range, and the forward earnings estimate implies a much lower PE than the trailing figure, hinting at potential earnings improvement. The dividend yield is modest, backed by positive free cash flow and a payout ratio comfortably below the majority of earnings, suggesting sustainability. Analyst consensus remains bullish with a “buy” rating and price targets in the upper range of expectations, reflecting optimism despite the valuation stretch. The Fear & Greed index is in the extreme greed zone, which may signal market euphoria. Given these mixed signals, investors should weigh the overvaluation against the steady cash generation and dividend stability.
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 6/10
Key Factors
- bearish MACD momentum
- price well above DCF fair value
- moderate volatility offering short‑term opportunities
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- analyst buy consensus
- sustainable dividend
- potential earnings improvement
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- global exposure to flavor and fragrance demand
- steady cash flow generation
- valuation may compress over time
Key Metrics & Analysis
Financial Health
Revenue Growth-2.40%
Profit Margin5.06%
P/E Ratio42.4
ROE6.53%
ROA4.70%
Debt/Equity70.29
P/B Ratio2.8
Op. Cash Flow€772.3M
Free Cash Flow€229.3M
Technical Analysis
TrendNeutral
RSI55.8
Support€72.20
Resistance€78.12
MA 20€74.52
MA 50€73.39
MA 200€74.45
MACDBearish
VolumeStable
Fear & Greed Index88.66
Valuation
Fair Value€10.06
Target Price€92.06
Upside/Downside21.97%
GradeOvervalued
TypeValue
Dividend Yield1.69%
Risk Assessment
Beta-0.00
Volatility22.98%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.